Abstract | BACKGROUND: METHODS: Five databases (PubMed, Embase, Cochrane Library, Web of Science and ClinicalTrials.gov) were searched using the following search terms: " hairy cell leukemia" or " leukemia, hairy cell" AND "relapse" or "recurrence". We included only prospective clinical trials with outcome data. RESULTS:
Vemurafenib monotherapy was evaluated in two separate arms of a phase 2 trial. In the US arm (n=24), the ORR was 100% (CR 42%; PR 58%). In the Italian arm (n=26), the ORR was 96% (CR 35%; PR 62%). In a phase 2 study (n=25), the combination of vemurafenib and rituximab showed CR of 100%. The combination of BR achieved an ORR of 100% whereas CR was 50% and 67% at a bendamustine dose of 70mg/m2 (n=6) and 90 mg/m2 (n=6) respectively. In a phase 3 trial, moxetumomab pasudotox (n=80) had an ORR of 75% (CR 41%). Single agent Ibrutinib (n=37) had an ORR of 54%. Therapies were generally well tolerated. CONCLUSION: Novel agents have good efficacy in HCL in patients with multiple relapses.
|
Authors | Raheel Siddiqui, Muhammad Sardar, Moazzam Shahzad, Jemin Jose, Insija Selene, Zunaira Shah, Anum Qureshi, Madeeha Shafqat, Rimsha Kashif, Maheen Ahmad, Alex Mejia-Garcia, Faiz Anwer |
Journal | Clinical lymphoma, myeloma & leukemia
(Clin Lymphoma Myeloma Leuk)
Vol. 21
Issue 10
Pg. 659-666
(10 2021)
ISSN: 2152-2669 [Electronic] United States |
PMID | 34275772
(Publication Type: Journal Article, Systematic Review)
|
Copyright | Copyright © 2021 Elsevier Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Adolescent
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Child
- Female
- Humans
- Leukemia, Hairy Cell
(drug therapy)
- Male
|